Finally Bring an End to RAS Driven Cancers
Explore Novel Strategies, Identify Rational Anti-RAS Combination Strategies & Accelerate the Translation of Next Generation of Mutant-Targeted RAS Therapies into Human Clinical Trials
As the first KRAS inhibitors reach the clinic and show promising opportunities to address unmet clinical need, the 2nd RAS- Targeted Drug Development Summit 2020 returns to drive forward the clinical translation of first generation Anti-RAS therapies.
The two-track 2nd RAS- Targeted Drug Development Summit 2020 will be your comprehensive and definitive platform, dedicated to bringing together the largest community of RAS experts from large pharma, innovative biotech and research institutes to capitalize on the emerging therapeutic and therapeutic opportunity to finally drug the previously “undruggable” RAS proteins.
"The field of RAS inhibitory drugs has exploded in the last few years and this meeting will be an excellent opportunity to catch up on the latest developments in this fast-moving area”
Julian Downward, Associate Research Director, Francis Crick Institute
“The RAS-Targeted Summit is a leading forum for publicizing and exchanging ideas about the therapeutic targeting of this crucial driver of malignancy. We look forward to seeing emerging data and presenting our contributions to the effort to develop treatments with broad patient impact.”
Frank Haluska, President & CEO, Anchiano Therapeutics